Effects of topical anti-inflammatory and antiallergic eyedrops on prostaglandin E2-induced aqueous flare elevation in pigmented rabbits.
OBJECTIVE
To evaluate the role of topical instillation of anti-inflammatory or antiallergic agents on experimental elevation of aqueous flare induced by prostaglandin E2 (PGE2) in pigmented rabbits.


METHODS
Transcorneal diffusion of PGE2, 25 microg/mL (7.09 x 10 (-2)mmol/L), by means of a glass cylinder produced aqueous flare elevation. Anti-inflammatory or antiallergic agents were topically administered once or twice before PGE2 application. Aqueous flare was measured with a laser flare-cell meter. Results are given as mean +/- SD.


RESULTS
Double instillations of 0.1% betamethasone sodium phosphate and 0.1% fluorometholone acetate at 4 and 2 hours before PGE2 application inhibited 61% +/- 11% and 46% +/- 14%, respectively, of flare elevation. Double instillations of 0.1% diclofenac sodium and 0.1% pranoprofen at 4 and 2 hours before PGE2 application did not inhibit flare elevation. Double instillations of 0.1% betamethasone, 0.1% fluorometholone, 0.1% diclofenac, and 0.1% pranoprofen at 1 and 0.5 hour before PGE(2) application inhibited 16% +/- 10%, 16% +/- 6%, 24% +/- 9%, and 23% +/- 10%, respectively, of flare elevation. Double instillations of 2% cromolyn sodium, 0.5% tranilast, 0.025% levocabastine hydrochloride, 0.1% pemirolast potassium, and 0.01% ibudilast at 1 and 0.5 hour before PGE2 application did not inhibit flare elevation. Single instillation of 0.1% betamethasone 6 hours before PGE2 application inhibited 88% of PGE2-induced aqueous flare elevation. Single instillation of 0.1% diclofenac 1 hour before PGE2 application inhibited 23% of PGE2-induced aqueous flare elevation.


CONCLUSIONS
Betamethasone needed several hours after topical instillation to inhibit flare elevation, but diclofenac needed 1 hour. Antiallergic agents did not affect disruption of the blood-aqueous barrier in rabbits.


CONCLUSIONS
Corticosteroid eyedrops may need several hours from instillation to show action.
Hayasaka
Yoriko
Y
Department of Ophthalmology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan. ophthal@ms.toyama-mpu.ac.jp
Hayasaka
Seiji
S
Zhang
Xue-Yun
XY
Nagaki
Yasunori
Y
D000287:Administration, Topical; D000818:Animals; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D001082:Aqueous Humor / Q000187:drug effects* / Q000378:metabolism; D015232:Dinoprostone / Q000633:toxicity; D004359:Drug Therapy, Combination; D008297:Male; D009883:Ophthalmic Solutions; D011817:Rabbits; D013256:Steroids; D013997:Time Factors; D014606:Uveitis, Anterior / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*
D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D009883:Ophthalmic Solutions; D013256:Steroids; D015232:Dinoprostone